South San Francisco, CA, United States of America

Anasuya Saha

This inventor holds 4 USPTO granted patents and 2 published patent applications. Top assignee: Intervet Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anasuya Saha. Retrieved from https://idiyas.com/inventor/anasuya-saha

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Anasuya Saha - Innovator in Coronavirus Treatment

Introduction

Anasuya Saha is an inventor based in Fremont, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of treatments for coronavirus infections. His innovative work focuses on creating single-domain antibodies and polypeptides that can effectively target multiple coronaviruses.

Latest Patent Applications

Anasuya Saha's notable patent application is titled "POLYPEPTIDES EFFECTIVE AGAINST MULTIPLE CORONAVIRUSES." This application discloses single-domain antibodies that can bind separately to at least two spike proteins from different coronaviruses. Additionally, it presents polypeptides that possess multiple coronavirus spike-protein binders, which can neutralize at least two different coronaviruses. These advancements hold promise for treating coronavirus infections.

Conclusion

Anasuya Saha's work in developing effective treatments against multiple coronaviruses showcases his dedication to innovation in biotechnology. His contributions are vital in the ongoing fight against viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…